5 completed, 1 active not recruiting, 1 terminated. 7 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 7 | Completed 5, Active not recruiting 1, Terminated 1 |
| Phase 2 | 1 | Completed 1 |
Follow Mavacamten: new trials by email Literature Review of Mavacamten trials Research Report on Mavacamten
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy Mavacamten, Placebo - Cardiomyopathy, Hypertrophic | Phase 3 | Active not recruiting | Bristol-Myers Squibb | 44 | 2024-04-17 | 2025-12-19 |
| A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy Mavacamten, Placebo - Cardiomyopathy, Hypertrophic | Phase 3 | Terminated | Bristol-Myers Squibb | 580 | 2022-12-14 | 2026-09-18 |
| A Study of Mavacamten in Obstructive Hypertrophic Cardiomyopathy Mavacamten - Cardiomyopathy, Hypertrophic Obstructive | Phase 3 | Completed | Bristol-Myers Squibb | 38 | 2022-08-19 | 2026-01-27 |
| A Study to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive HCM Mavacamten, Placebo - Obstructive Hypertrophic Cardiomyopathy | Phase 3 | Completed | LianBio LLC | 81 | 2022-01-04 | 2024-09-19 |
| A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy Mavacamten, Placebo - HOCM, Hypertrophic Obstructive Cardiomyopathy | Phase 3 | Completed | Bristol-Myers Squibb | 112 | 2020-07-06 | 2025-05-23 |
| A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM mavacamten - Hypertrophic Cardiomyopathy, Obstructive Hypertrophic Cardiomyopathy | Phase 2 / Phase 3 | Completed | Bristol-Myers Squibb | 314 | 2018-09-27 | 2026-02-20 |
| Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy mavacamten, Placebo - Obstructive Hypertrophic Cardiomyopathy | Phase 3 | Completed | MyoKardia, Inc. | 251 | 2018-05-29 | 2021-10-04 |
Cardiomyopathy, Hypertrophic (7)
Bristol-Myers Squibb (5) · LianBio LLC (1) · MyoKardia, Inc. (1)
United States (5) · France (4) · Germany (4) · Italy (4) · Spain (4) · United Kingdom (4) · Belgium (3) · Czechia (3) · Denmark (3) · Israel (3) · Netherlands (3) · Poland (3) · Portugal (3) · Australia (2) · Canada (2)
Shuyang Zhang, M.D., Ph.D. (1)
PMID 42636950, PMID 39217450, PMID 32498620, PMID 32871100, PMID 34004177, PMID 34018809, PMID 34038706, PMID 34081217, PMID 34907813, PMID 34915982, PMID 35718845, PMID 35798455, PMID 35902155, PMID 36335531, PMID 36335645, PMID 36652223, PMID 37336533, PMID 37639243, PMID 37639259, PMID 37855754, PMID 37961906, PMID 38176782, PMID 38625800, PMID 38695527, PMID 39221824, PMID 39254622, PMID 39349158, PMID 39349160, PMID 39495835, PMID 39556124, PMID 39653325, PMID 39909647, PMID 40299193, PMID 40425241, PMID 40632050, PMID 40864018, PMID 40888717, PMID 41038603, PMID 41910394, PMID 42165935, PMID 42179278, PMID 42251960
2023 (2)